BioCentury | Oct 7, 2013
Clinical News

Intranasal sumatriptan powder: Phase I data

...significantly lower Cmax and total systemic exposure compared to both oral Imitrex and 6 mg Imitrex...
...commercialize AVP-825 from OptiNose (see BioCentury, July 15). GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Imitrex...
BioCentury | Apr 15, 2013
Company News

NovaDel, Suda deal

...the day before the deal was announced. The deal includes IP related to NovaMist, plus NVD-201...
BioCentury | Jan 7, 2013
Company News

NovaDel, Suda deal

...The companies declined to disclose financial terms. The option covers IP related to NovaMist, plus NVD-201...
BioCentury | Nov 2, 2009
Clinical News

Sumatriptan: Phase I data

...using the Imitrex STATdose needle-based autoinjector. Overall safety profiles were comparable between Sumavel DosePro and Imitrex...
...and granted exclusive European rights to Desitin Arzneimittel last year (see BioCentury, March 24, 2008). Imitrex...
BioCentury | Aug 31, 2009
Product Development

Third time's a charm

...and for the acute treatment of cluster headache episodes based on studies demonstrating bioequivalence with Imitrex...
...pharma's large primary care presence, said Hawley. The labels for both Sumavel DosePro and injectable Imitrex...
...nausea and vomiting, a rapid-acting subcutaneous triptan will be the best option. Compared with injectable Imitrex...
BioCentury | Sep 8, 2008
Clinical News

Sumatriptan oral spray: Pilot trial data

...patients with documented slow response to 50 mg Imitrex sumatriptan tablet, 30 and 40 mg sumatriptan oral spray...
...p<=0.011). Significantly more patients responded to 20, 30 or 40 mg sumatriptan oral spray vs. 50 mg Imitrex...
...by 2 hours. Responses to all 3 doses were comparable to 100 mg Imitrex tablet. Imitrex...
BioCentury | Jul 25, 2008
Financial News

NuPathe raises $30 million

...delivering sumatriptan via iontophoresis. Sumatriptan, which is marketed for migraine by GlaxoSmithKline (LSE:GSK; NYSE:GSK) as Imitrex...
BioCentury | Jul 7, 2008
Product Development

Telcagepant vs triptans

...Placebo [n=94] 27% 25 mg Imitrex [n=298] 52% 50 mg Imitrex [n=296] 61% 100 mg Imitrex...
BioCentury | Jul 7, 2008
Product Development

Cleaner than triptans

...cardiovascular risk is what will put MK-0974 over the top, even though the leading triptan, Imitrex...
...other triptans like Imitrex, but noted the triptans available on the market have similar profiles. Imitrex...
BioCentury | Jul 7, 2008
Clinical News

NP101: Phase I data

...no serious adverse events. Data were presented at the American Headache Society meeting in Boston. Imitrex...
Items per page:
1 - 10 of 48